Inhibitory effect of a selective thromboxane A2receptor antagonist, EP 092, on platelet aggregation in whole bloodex vivoandin vivo

View Full Paper

Ask AI

Bookmark

Why the study?

Does EP 092 inhibit platelet aggregation in animal models?

Population

Guinea-pigs, Rhesus monkeys, and anaesthetized rabbits

Design

Preclinical

Authors

Discussion

Hypothesis-generating for EP 092 as an antiplatelet agent; human trials needed before clinical consideration.

Does EP 092 inhibit platelet aggregation in animal models?

Population

Guinea-pigs, Rhesus monkeys, and anaesthetized rabbits

Intervention

EP 092 (selective prostaglandin H2/thromboxane A2 receptor antagonist) administered intravenously (0.1-10 mg/kg) or orally (1.0-10.0 mg/kg)

Outcome

Platelet aggregatory responses to collagen and thrombin ex vivo and in vivosurrogate

EP 092 effectively inhibits thromboxane-dependent platelet aggregation in multiple animal models, supporting its potential as an antiplatelet agent.

Booth et al. (1989) studied this question.

View Full Paper

Ask AI

Bookmark